[{"id":"711124ce-0659-42bd-8b65-60940e5975b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05415072","created_at":"2022-06-10T12:58:54.272Z","updated_at":"2024-07-02T16:35:07.121Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","source_id_and_acronym":"NCT05415072","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" GNAQ","pipe":"","alterations":" ","tags":["GNAQ"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DYP688"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-04-29"}]